This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
Tilly's (TLYS)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
TLYSPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Are Options Traders Betting on a Big Move in UFP Technologies Stock?
by Zacks Equity Research
Investors need to pay close attention to UFP Technologies stock based on the movements in the options market lately.
UFPTNegative Net Change
medical medical-devices
BSX vs. RMD: Which Medical Device Stock Is the Stronger Play Now?
by Moumi Mondal
Boston Scientific edges out Resmed as WATCHMAN momentum, EP gains and acquisitions fuel stronger recent price performance in a growing medical device market.
BSXPositive Net Change RMDNegative Net Change
medical medical-devices
Should Myriad Genetics Stock Stay in Your Portfolio Right Now?
by Zacks Equity Research
MYGN shows growth potential from new genetic test launches and a refreshed CCC strategy, but revenue pressure from GeneSight coverage loss remains a drag.
ILMNNegative Net Change MYGNNegative Net Change PODDNegative Net Change BTSGNegative Net Change
medical medical-devices
3 Stocks Likely to Gain From Rising HSA Contribution & Medicare Premium
by Indrajit Bandyopadhyay
Rising HSA limits and higher Medicare premiums in 2026 could lift demand for chronic care devices from DexCom, ResMed and Masimo.
RMDNegative Net Change MASIPositive Net Change DXCMPositive Net Change
medical medical-devices
Reasons to Add Cooper Companies Stock to Your Portfolio Now
by Zacks Equity Research
COO's revenues are showing strong growth as MyDay and MiSight drive momentum, while restructuring savings and buybacks bolster long-term upside despite near-term risks.
COOPositive Net Change CORPositive Net Change PODDNegative Net Change PAHCNegative Net Change
medical medical-devices
Reasons to Hold Veeva Systems Stock in Your Portfolio for Now
by Zacks Equity Research
VEEV's strong Q3, expanding AI strategy and major life sciences partnerships fuel growth despite rising costs.
BSXPositive Net Change ISRGNegative Net Change VEEVNegative Net Change MEDPPositive Net Change
medical medical-devices
Omeros Gets FDA Approval for YARTEMLEA as First Therapy for TA-TMA
by Zacks Equity Research
OMER wins FDA approval for YARTEMLEA, the first TA-TMA therapy, marking its first commercial product and a shift to revenue generation.
BSXPositive Net Change OMERPositive Net Change ATRCPositive Net Change PAHCNegative Net Change
medical medical-devices
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
by Zacks Equity Research
GKOS appears well-positioned for long-term growth as iDose TR adoption accelerates and Epioxa secures FDA approval, although reimbursement and execution risks remain.
CORPositive Net Change PODDNegative Net Change PAHCNegative Net Change GKOSNegative Net Change
medical medical-devices
3 Medical Instrument Stocks to Counter Industry Woes Using GenAI
by Moumi Mondal
VCYT, IDXX and ISRG ride on genAI-powered growth as medical instruments evolve, even with weak industry returns and cost pressures.
ISRGNegative Net Change IDXXNegative Net Change VCYTPositive Net Change
artificial-intelligence medical medical-devices
EW Wins FDA Approval for SAPIEN M3 as First Transseptal TMVR Therapy
by Zacks Equity Research
Edwards Lifesciences wins FDA approval for SAPIEN M3, the first transseptal TMVR, expanding minimally invasive options for high-risk mitral regurgitation patients.
EWPositive Net Change EDAPNegative Net Change VCYTPositive Net Change AORTNegative Net Change
medical medical-devices
Mitek Systems (MITK)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
MITKPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Hologic's GYN Surgical Segment Looks Poised for Long-Term Growth
by Moumi Mondal
HOLX's GYN Surgical unit gains momentum as the demand for gynecological devices rises globally, driven by innovation, M&A and strong overseas adoption.
ABTPositive Net Change BDXPositive Net Change HOLXPositive Net Change
medical medical-devices
Should You Continue to Hold BRKR Stock in Your Portfolio?
by Zacks Equity Research
Bruker's innovation pipeline and acquisitions support long-term growth, but macro pressures and funding risks cloud the stock's near-term outlook.
ILMNNegative Net Change PODDNegative Net Change BRKRNegative Net Change BTSGNegative Net Change
medical medical-devices
Reasons to Retain Baxter International Stock in Your Portfolio Now
by Zacks Equity Research
BAX is reshaping its portfolio following the divestiture of Kidney Care, focusing on surgical strength, deleveraging and tighter execution to rebuild momentum.
BAXPositive Net Change CORPositive Net Change PODDNegative Net Change PAHCNegative Net Change
medical medical-devices
Is ISRG's 20% Procedure Growth the New Normal or a Peak?
by Indrajit Bandyopadhyay
ISRG posts 20% Q3 procedure growth as da Vinci and Ion volumes accelerate, but investors question if product cycles and timing effects can sustain it.
ISRGNegative Net Change STXSNegative Net Change ZBHNegative Net Change
medical medical-devices
SOLV Acquires Acera Surgical to Expand Advanced Wound Care Portfolio
by Zacks Equity Research
Solventum buys Acera Surgical for $725M upfront to enter tissue matrices, expanding MedSurg and wound care.
MDNegative Net Change BDSXPositive Net Change BTSGNegative Net Change SOLVPositive Net Change
medical medical-devices
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
by Zacks Equity Research
ANGO benefits from NanoKnife, clinical milestones and a balanced portfolio despite tariff headwinds.
BSXPositive Net Change ANGOPositive Net Change ISRGNegative Net Change MEDPPositive Net Change
medical medical-devices
HIMS vs. TDOC: Which Telehealth Stock Looks More Compelling?
by Debanjana Dey
Hims & Hers and Teladoc Health are expanding virtual care in different ways, but which telehealth platform looks more compelling right now? Let's dive in.
TDOCPositive Net Change HIMSNegative Net Change
medical medical-devices
Should You Buy X4 Pharmaceuticals (XFOR) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
XFORNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Midland States Bancorp (MSBI) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
MSBIPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
How Well Is Boston Scientific Placed for Long-Term Endoscopy Growth?
by Moumi Mondal
BSX's Endoscopy unit targets an $8B market, spanning pancreaticobiliary, surgery and obesity, with plans to outgrow the market.
ABTPositive Net Change BSXPositive Net Change EWPositive Net Change
medical medical-devices
Is Quest Diagnostics Stock a Right Pick for Your Portfolio Now?
by Zacks Equity Research
DGX banks on acquisitions, advanced diagnostics and cost discipline, even as debt levels and macro pressures pose risks.
DGXNegative Net Change ILMNNegative Net Change PODDNegative Net Change BTSGNegative Net Change
medical medical-devices
Intuitive Surgical vs. Stryker: Which MedTech Stock Has More Upside?
by Indrajit Bandyopadhyay
Intuitive Surgical's robotics-first model, recurring revenue base, and margin leverage differentiate it from Stryker in terms of upside potential today.
SYKPositive Net Change ISRGNegative Net Change
medical medical-devices
Here's Why You Should Retain Merit Medical Stock in Your Portfolio Now
by Zacks Equity Research
Merit Medical shows resilience despite 2025 share pressure, supported by cardiovascular growth, margin expansion and WRAPSODY CIE momentum.
BSXPositive Net Change MASIPositive Net Change MMSIPositive Net Change CORPositive Net Change
medical medical-devices